GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NexGel Inc (NAS:NXGL) » Definitions » Capex-to-Operating-Cash-Flow

NXGL (NexGel) Capex-to-Operating-Cash-Flow : 0.00 (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is NexGel Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

NexGel's Capital Expenditure for the three months ended in Sep. 2024 was $-0.01 Mil. Its Cash Flow from Operations for the three months ended in Sep. 2024 was $-1.22 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


NexGel Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for NexGel's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NexGel Capex-to-Operating-Cash-Flow Chart

NexGel Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial - - - - -

NexGel Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NexGel's Capex-to-Operating-Cash-Flow

For the Medical Instruments & Supplies subindustry, NexGel's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NexGel's Capex-to-Operating-Cash-Flow Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NexGel's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where NexGel's Capex-to-Operating-Cash-Flow falls into.



NexGel Capex-to-Operating-Cash-Flow Calculation

NexGel's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.696) / -3.236
=N/A

NexGel's Capex-to-Operating-Cash-Flow for the quarter that ended in Sep. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.013) / -1.216
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NexGel  (NAS:NXGL) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


NexGel Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of NexGel's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


NexGel Business Description

Traded in Other Exchanges
N/A
Address
2150 Cabot Boulevard West, Suite B, Langhorne, PA, USA, 19047
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating, and cross-linking technologies.
Executives
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Drapczuk Adam E Iii officer: Chief Financial Officer 6 OAKMONT TERRACE, EAST WINDSOR NJ 08520
Steven Mark Glassman director 99 LEWIS POINT ROAD, FAIR HAVEN NJ 07704
Nachum Stein director QUADRAX CORP, 618 MAIN ST PO BOX 1001, WEST WARWICK RI 02893
Adam R. Levy officer: CEO and President 2 AVENUE OF TWO RIVER SOUTH, RUMSON NJ 07760
Scott Robert Henry director 34A ATLANTIC AVE., COHASSET MA 02025
David Stefansky director 850 THIRD AVENUE, SUITE 1801, NEW YORK NY 10022
Yaakov Spinrad director 3450 OAKTON ST, SKOKIE IL 60076
Miranda Jayne Toledano director C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135
Bezalel Partners Llc 10 percent owner C/O KRIEGER & PRAGER LLP, 39 BROADWAY, STE 920, NEW YORK NY 10006
David Ian Johnson director, officer: Chief Executive Officer C/O ALLIQUA, INC., 850 3RD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Adynxx, Inc. 10 percent owner 100 PINE ST., STE. 500, SAN FRANCISCO CA 94111